Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nascent Biotech Inc NBIO

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a... see more

Recent & Breaking News (OTCQB:NBIO)

Nascent Biotech & Manhattan BioSolutions Participate In a Panel Discussion On The TB Vaccine Development For COVID-19

Accesswire August 4, 2020

Nascent Biotech Announces Collaboration with Syracuse University - Advancing COVID-19 Research

Accesswire July 28, 2020

Nascent Biotech Officers Convert Liability to Stock in the Company

GlobeNewswire July 8, 2020

Nascent Biotech Appoints Chief Medical Consultant in Charge of COVID-19 Research

GlobeNewswire June 24, 2020

Nascent Biotech to Begin Animal Model Studies for Pritumumab Against Coronaviruses and COVID-19

GlobeNewswire June 17, 2020

Nascent Biotech's CEO Provides Corporate Updates on Phase I Brain Cancer Trial and COVID-19 Development Initiative on SNN Network

Accesswire June 3, 2020

Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug

GlobeNewswire May 27, 2020

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

GlobeNewswire May 12, 2020

Nascent Biotech Terminates Equity Line of Credit with Triton Funds

GlobeNewswire May 6, 2020

Nascent Biotech Provides Shareholder Update on COVID-19 Therapy and Brain Cancer Trials

GlobeNewswire April 22, 2020

Nascent Biotech to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020

GlobeNewswire April 21, 2020

Nascent Biotech, Inc. Developing Therapy with Indications for COVID-19

GlobeNewswire April 9, 2020

NascentBiotech's Independent Consultants Have Begun Research on Pribumumab as a Potential Therapeutic Agent Against (Coronavirus) Covid-19

Accesswire April 7, 2020

Nascent Biotech has Begun In Vitro Studies as a Potential Therapeutic Agent Against COVID-19

Accesswire March 19, 2020

Nascent Biotech Investigation Drug Product, Pritumumab, to be Studied as a Potential Therapeutic agent against (Coronavirus) Covid-19

Accesswire March 3, 2020

Nascent Biotech, Inc. CEO Interviewed by The Wall Street Analyzer

GlobeNewswire February 5, 2020

Nascent Biotech Founder, Dr. Mark Glassy, Will Present at the Clinical Operation in Oncology Trials Meeting, in San Diego in February

GlobeNewswire January 30, 2020

Nascent Biotech, Inc. Featured in New Research Update

GlobeNewswire January 15, 2020

Nascent Biotech Receives One Million Dollar Commitment From TRITON FUNDS LP

GlobeNewswire September 11, 2019

Nascent Biotech Has Entered into an Agreement to Perform Phase I Clinical Study for Brain Cancer

GlobeNewswire August 19, 2019